Spa K 940 / 423. Abstract n K 940

Similar documents
Worrying trends in antibiotic use in French hospitals,

Stratégie et action européennes

Successful stewardship in hospital settings

Junior doctors knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland

Nosocomial Infections: What Are the Unmet Needs

6-7 November Ministry of Health, Youth, Sport and Voluntary Sector. Pierre Laroque Amphitheater

ECDC activities on antimicrobial resistance & healthcare-associated infections (ARHAI Programme) Ülla-Karin Nurm, ECDC Tallinn, 13 May 2013

Perspectives. i s o l a t e s : t h e Fr e n c h e x p e r i e n c e. 4 EUROSURVEILLANCE Vol. 13 Issue November

What is the problem? Latest data on antibiotic resistance

Measures relating to antimicrobial resistance (AMR)

Antimicrobial Stewardship Esperienza Torinese

Hospital ID: 831. Bourguiba Hospital. Tertiary hospital

Antimicrobial Resistance Prevention (Action Package: Prevent-1) Putting AMR on the priority list: Sweden Dr. Nils Anders Tegnell, Director, The

The surgical site infection risk in developing countries. Yves BUISSON Société de Pathologie Exotique

Initiatives taken to reduce antimicrobial resistance in DK and in the EU in the health care sector

Promoting Appropriate Antimicrobial Prescribing in Secondary Care

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts

ESAC s Surveillance by Point Prevalence Measurements. by author

Antimicrobial stewardship

Perspectives. i s o l a t e s : t h e Fr e n c h e x p e r i e n c e

Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices

Consultation on a draft Global action plan to address antimicrobial resistance

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Integrated Analysis of Data on Resistance and Antimicrobial Consumption from the Human and Animal Sectors in Europe The JIACRA Report

Antimicrobial use and Antimicrobial resistance: chapter 6.7 and 6.8 of the OIE Terrestrial Animal Health

POTENTIAL STRUCTURE INDICATORS FOR EVALUATING ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN EUROPEAN HOSPITALS

Stratégies et actions au niveau européen et international: populations humaines

Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe

Reducing nosocomial infections and improving rational use of antibiotics in children in Indonesia

POINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals. Koen Magerman Working group Hospital Medicine

Geriatric Mental Health Partnership

Medicines use in China

Healthcare-associated Infections and Antimicrobial Use Prevalence Survey

COST-EFFECTIVENESS OF INTERVENTIONS TO LIMIT THE SPREAD OF AMR A PERSPECTIVE FROM THE OECD

IDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital

Downloaded from:

Antimicrobial Stewardship Northern Ireland

European Antibiotic Awareness Day

EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK

Appropriate antimicrobial therapy in HAP: What does this mean?

Antimicrobial stewardship in companion animals: Welcome to a whole new era

Birgit Ross Hospital Hygiene University Hospital Essen Essen, Germany. Should we screen for multiresistant gramnegative Bacteria?

Healthcare Facilities and Healthcare Professionals. Public

OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play

EFSA s activities on Antimicrobial resistance in the food chain. Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA

SECOND REPORT FROM THE COMMISSION TO THE COUNCIL

The evolutionary epidemiology of antibiotic resistance evolution

Anne Santerre Henriksen- Florence February 17th

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Antibiotic Stewardship in the LTC Setting

Antimicrobial Stewardship Program: Local Experience

Professional recognition for medical microbiology. Dr. K. Magerman Jessa Ziekenhuis Hasselt UHasselt

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France

Best Practices: Goals of Antimicrobial Stewardship

Multi-drug resistant microorganisms

Reassessment of intravenous antibiotic therapy using a reminder or direct counselling

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

How is Ireland performing on antibiotic prescribing?

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis

Antibiotics and resistance in the WHO Regional Office for Europe. Dr Nienke van de Sande On behalf of the AMR Working Group

Guidelines on prescribing antibiotics. For physicians and others in Denmark

Implementing a tele-expertise system to optimise the antibiotic use and stewardship: The case of the Montpellier University Hospital (France)

Changing behaviours in antimicrobial stewardship

FDA Antibiotic Resistance Strategy

Stewardship tools. Dilip Nathwani Ninewells Hospital and Medical School Dundee, UK

Antimicrobial consumption and resistance in humans in the EU and conclusions from the ECDC-EFSA- EMA JIACRA report

The threat of multidrug-resistant microorganisms and how to deal with it in Europe

Quality indicators and outcomes in the devolved nations Scotland

REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT

Human health impacts of antibiotic use in animal agriculture

Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health

TREAT Steward. Antimicrobial Stewardship software with personalized decision support

Consumption of antibiotics in hospitals. Antimicrobial stewardship.

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

ake National Point Prevalence Survey of Healthcare Associated Infections, Device usage and Antimicrobial use in Long-Term Care Facilities 2017 HALT-3

Halting Infections in Long Term Care

Models for stewardship in Hospital - UK Models Philip Howard Consultant Antimicrobial Pharmacist

European Medicines Agency role and experience on antimicrobial resistance

ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials

Antimicrobial use in animals: OIE collection of data on antimicrobial agents used in animals (2015)

Stewardship: Challenges & Opportunities in the Gulf Region

Antimicrobial utilization: Capital Health Region, Alberta

Summary of the latest data on antibiotic consumption in the European Union

Antimicrobial resistance: the challenges for animal health

Antimicrobial Stewardship Strategy: Antibiograms

Physician Rating: ( 23 Votes ) Rate This Article:

Specific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot study

CLSI vs. EUCAST. What is EUCAST? Structure of EUCAST CLSI. Where they fit? SASCM WORKSHOP 5/24/2014

Please distribute a copy of this information to each provider in your organization.

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals

Antibiotic resistance in West Africa

Impact of Antimicrobial Stewardship Program

Transcription:

K 940 / 423 Dr Jérôme ROBERT Bactériologie-Hygiène UPMC - Site Pitié-Salpêtrière 91 Bd de l hôpital - 75013 PARIS - France «jerome.robert@psl.aphp.fr» Dr Rémy GAUZIT Réanimation Ste Marthe Hôtel Dieu de Paris 1 place du Parvis Notre Dame -75004 PARIS - France «remy.gauzit@htd.aphp.fr» Abstract n K 940 Background. Analysis of antimicrobial prescription according to patients characteristics is of major interest to prevent resistance. Method. One-day prevalence survey in a sample of hospitalized patients in 38 voluntary French hospitals by using a questionnaire adapted from ESAC. Results. A total of 3964 patients were surveyed (39% in medicine, 29% in surgery, 12% in ICUs, and 20% in other departments), including 1276 (32%) with an antimicrobial treatment. Among the latter, 35% received B-lactams+inhibitors, 24% fluoroquinolones (FQ), 22% 3rd generation cephalosporins. 51% were treated for community infections, and 39% for nosocomial infections (10% unknown), including 22% and 34% (p<.01) for >7 days at the date of survey, respectively. 1

34% of the patients with community infections received >1 drug vs 48% among those with nosocomial infections (p<.01). A total of 23% of patients with antibiotics did not have any microbiological sample drawn (64% among community infections, 24% among nosocomial infections, and 12% among infections of undetermined origin), including 19% with a duration of treatment >7 days at the date of survey. Patients with proven MDR bacteria (8%) were significantly treated with > 1 drug, for a longer duration of time than others. Conclusion. Despite a large dissemination of guidelines during the last years, 1/4 of patients with community infections received >7 days of treatment, and 1/3 more than 1 drug. More surprisingly, a large proportion of all patients received antimicrobials for more than 1 week without documented infection. Finally, the large proportion of patients receiving FQ should be put in perspective with increased resistance rates Consequently, education and antibiotic stewardship should be implemented in French hospitals. Survey of Antibiotic Prescriptions (SPA) in a Network of French Hospital in 2009 Jerôme Robert 1, Yves Pean 2, Jean-Pierre Bedos 3, Emanuelle Varon 4, Jean Paul Stahl 5, Alain Lepape 6, Jean Pierre Bru 7, Xavier Bertrand 8, Rémy Gauzit 9 and the Spilf 10 (Société de pathologie in 1 UFR Medecine PM Curie - ONERBA, Paris; 2 IMM, Paris; 3 CH Versailles; 4 HEGP, Paris; 5 CHU Grenoble; 6 CHU Lyon Sud; 7 CH Annecy; 8 CHU Besançon; 9 CHU Hôtel Dieu, Paris; 10 Société de Pathologie Infectieuse de Langue Française 2

Background In Europe, it is estimated that about 175 000 patients are dying each year from untreatable infection (European Academics Scientific Advisory Counci 2008) Better use of antimicrobials is key to prevent bacterial resistance to antibiotics (French National Plan for Antibiotic Preservation 2002) France is one of the countries with the highest consumption of antibiotics in Europe (ESAC 2008) The French Health Agency recommends to evaluate quality of antibiotic use (Stratégie d antibiothérapie et prévention des résistances bactériennes en établissement de santé - Avril 2008) There is a lack of data on antibiotic use at the national level in France, besides total consumption 1 Objectives of the study To valuate the proportion of inpatients receiving antibiotics and antifungals for treatment of infection (antimicrobial prophylaxis excluded) in a large number of French hospitals To describe characteristics of patients receiving antimicrobials To valute the faisability of a large scale study by a pilot survey To improve the representativeness of French data in European networks 2 3

Methods Observational one-day prevalence study (18 novembre 2009, European Antibiotic Day) Voluntary hospitals - from all patients in one ward to all inpatients Questionnaire adapted from the European (ESAC) and the French Health Agency Questionnaires For all inpatients, collection of: Basic demographic data Risk factors for multidrug-resistant bacteria 3 Methods For patients receiving antibiotics, collection of: Antimicrobial treatment - date of start - drugs - route of administration, frequency Infection : - site - community vs nosocomial - foreign devices Microbiology - samples drawn - availability of results (microscopy, culture, susceptibility) Multidrug-resistant bacteria 4 4

Results 38 hospitals, 3 964 patients (n = 15 to 393) Age : 63 ± 20 years Female : 52 % Distribution of patients/type of ward Others Haematology Oncology ICU 11% 9% 12% 39% Medicine Surgery 29% 5 Antimicrobial treatment 1 276 inpatients/3 964 observed (32 %) receiving 1 antimicrobial the day of the study Proportion of patients receiving antimicrobials (ATB) / type of ward 6 5

Distribution of antimicrobials % of patients with 7 Type of infection 1 276 patients with antimicrobials 8 6

Combination of antimicrobials % of all patients with ATB 9 Combinations & type of infection Number of antimicrobial per patient 10 7

Treatment characteristics Overall, 56 patients (4.4%): no microbiological sample AND treatment > 7 days 11 Duration of treatment > 7 days (At the time of survey minimal duration of treatment) No statistical difference between ICUs and non-icu wards regarding the duration of treatment 12 8

Duration of treatment > 7 days (At the time of survey minimal duration of treatment) 13 Aminoglycosides treatment Among all patients with antibiotics, 8% had an aminoglycoside 6.8% among patients with community-acquired infections 8.4% among patients with hospital-acquired infections (no statistical difference - p = 0.31) Duration of treatment at the time of the survey (At the time of survey minimal duration of treatment) 11% 9% 79% 21% Community vs Nosocomial no statistical difference in duration of treatment 14 9

Multidrug-resistant bacteria (MDR) Among 1 194 strains isolated : 82 MDR (6,5 %) Treatment received 1 drug > 1 drug MDR + 40 % 60 % MDR - 60 % 40 % Median duration of treatment on the day of survey MDR + 9 j MDR - 4 j P <0.0001 15 Conclusions Despite a large amount of data 1/4 of community-acquired infections received - > 1 drug - and/or for a duration of > 7 days 5 % of inpatients treated for «infection» : - do not have any microbiological sample drawn - AND received > 7 days of antimicrobials Surprisingly, there is no difference in the duration of treatment between ICUs and other wards A large campaign of education of the physician should be implemented in French hospitals The role of a senior physician trained in antimicrobial therapy may be of interest, as recommended by the French Plan to Preserve Antibiotics 16 10